Advaxis completes enrollment of vanguard patient group in phase II clinical trial for cervical intraepithelial neoplasia

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia. This completes the enrollment of the vanguard group of patients for the first dosage group.

The clinical trial is a multicenter, randomized, placebo controlled, blinded clinical trial of ADXS11-001 -Advaxis' lead immunotherapeutic candidate. This trial is being conducted at the site by Dr. Keith Aqua, M.D. at the Institute for Women's Health & Body.


 Advaxis, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
AstraZeneca COVID-19 vaccine safe and effective in phase 3 U.S., Chile, and Peru trial